CATSCI - Co-founding shareholder successfully exited from CatSci, an innovation partner for drug research and development

CATSCI - Co-founding shareholder successfully exited from CatSci, an innovation partner for drug research and development

CatSci Ltd is a scientifically-led and commercially-minded partner for innovation, dedicated to developing economically and environmentally sustainable chemical processes. Their services include route scouting and selection for early development, and process design, development and optimisation for later phase pharmaceutical development.

Of the transaction, CEO and Co-founder Dr. Ross Burn said “this was a milestone transaction for CatSci, Alinea’s involvement and pragmatic advice enabled us to complete a deal, allowing us to focus on the next stage of exciting growth for CatSci and Capital Drug Development”.

The company has been experiencing transformational growth, with exceptional year on year performance.  In early 2020, one of the cofounders decided to exit and the other shareholders performed a management buy-out. In addition to this, the new company, Capital Drug Development (CDD), has been created to provide an integrated solution across the drug substance and drug product development process to enhance their service offering journey from “molecules to medicine”. Taking a long-term perspective, CDD intends to create or sustain 500 high-value jobs by 2030 and to establish a leading drug development organisation for the greater benefit of global healthcare.

Oliver Wadlow of Alinea said “it’s been a privilege to enable this transaction to happen, this type of deal sits right in the sweet spot for Alinea, so we were able to provide sound advice, helping the parties to find a balance on a number of matters”.